Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First? D. Moreno-Ramírez, A. Fernández-Orland, L. Ferrándiz

Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers M. Morellá Fernández, J. Balsalobre Yago, J. Martínez García, M. Peláez Gutiérrez, A. López Muñoz, A.I. Silvestre Ballesta, B. Sánchez Lafuente, I. Martínez Martín, P. Cerezuela Fuentes

Multicenter Analysis of the Surgical Management and Adjuvant Therapy of Patients With Melanoma and a Positive Sentinel Lymph Node Biopsy E. Samaniego-González, S. Podlipnik, S. Ribero, E. Nagore, A. Boada, J. Cañueto, S. Paradela, B. de Unamuno, P. Rodríguez-Jiménez, S. Puig, J. Malvehy, C. Carrera, G. Roccuzzo, C. Requena, E. Manrique-Silva, N. Richarz, A. Ruiz-Villanueva, V. Traves, S. España-Fernández, R. Botella-Estrada, M.A. González-Morán, A. Tejera-Vaquerizo